Vulvar Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VLV036 MIFTS: 46	Vulvar Disease Categories: Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Vulvar Disease

MalaCards integrated aliases for Vulvar Disease:

Name: Vulvar Disease ¹¹ ¹⁴ ⁷⁵

Vulvar Diseases ⁴³ ⁷¹

Vulvar Disorders ⁴¹

Classifications:

MalaCards categories:
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:2059

MeSH ⁴³ D014845

NCIt ⁴⁹ C27631

SNOMED-CT ⁶⁸ 5089007

UMLS ⁷¹ C0042994

Sources

Summaries for Vulvar Disease

MedlinePlus: ⁴¹ The vulva is the external part of a woman's genitals. Some problems you can have with the vulvar area include: Vaginitis or vulvovaginitis, swelling or infection of the vulva and vagina Skin problems due to allergy Vulvar cancer Vulvodynia, or vulvar pain Symptoms may include redness, itching, pain, or cracks in the skin. Treatment depends on the cause.

MalaCards based summary: Vulvar Disease, also known as vulvar diseases, is related to atrophic vulva and anogenital venereal wart, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulvar Disease is MIR223 (MicroRNA 223), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Acetylcholine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include vulva, skin and lymph node, and related phenotypes are Decreased viability and neoplasm

Disease Ontology: ¹¹ A female reproductive system disease that is located in the vulva.

Wikipedia: ⁷⁵ A vulvar disease is a particular abnormal, pathological condition that affects part or all of the vulva.... more...

Sources

Related Diseases for Vulvar Disease

Diseases related to Vulvar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 556)

#	Related Disease	Score	Top Affiliating Genes
1	atrophic vulva	32.0	KRT7 CDKN2A
2	anogenital venereal wart	30.6	TP53 GP5 CDKN2A
3	cervix uteri carcinoma in situ	30.1	TP53 GP5 CDKN2A
4	keratosis, seborrheic	30.0	TP53 PIK3CA KRT7 CDKN2A
5	mammary paget's disease	29.9	PIP KRT7 ERBB2
6	vulval paget's disease	29.8	PIP KRT7 ERBB2 CDKN2A
7	keratosis	29.8	TP53 PIK3CA HRAS EGFR CDKN2A
8	suppressor of tumorigenicity 3	29.6	TP53 CDKN2A
9	breast disease	29.6	TP53 MIR590 MIR499A MIR223 ERBB2
10	exanthem	29.6	KIT HRAS ERBB2 EGFR CD274
11	hemangioma	29.5	TP53 PTEN KRT7 KIT EGFR CDKN2A
12	papilloma	29.4	TP53 PTEN KRT7 ERBB2 EGFR CDKN2A
13	squamous cell carcinoma	28.8	TP53 PTEN PIK3CA NRAS KRT7 HRAS
14	vulva squamous cell carcinoma	28.5	TP53 PRICKLE2-AS1 PIK3CA MIR590 MIR4712 MIR3147
15	vulva cancer	27.4	TP53 PTEN PRICKLE2-AS1 PIP PIK3CA MIR590
16	vulvitis	11.0
17	vulvar dystrophy	11.0
18	ulceration of vulva	11.0
19	cervical basaloid squamous cell carcinoma	10.4	KRT7 CDKN2A
20	b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	10.4	TP53 CDKN2A
21	inverted transitional papilloma	10.4	KRT7 CDKN2A
22	endometrial transitional cell carcinoma	10.4	KRT7 CDKN2A
23	trachea carcinoma in situ	10.4	HRAS CDKN2A
24	pancreatic foamy gland adenocarcinoma	10.4	TP53 KRT7
25	tonsillar pillar cancer	10.4	EGFR CDKN2A
26	laryngeal adenoid cystic carcinoma	10.4	KRT7 KIT
27	cervical mucinous adenocarcinoma	10.4	KRT7 CDKN2A
28	vulvar sebaceous carcinoma	10.4	TP53 KRT7
29	breast hemangiopericytoma	10.4	KRT7 KIT
30	necrotizing sialometaplasia	10.4	TP53 KRT7
31	cervical adenocarcinoma	10.4	TP53 KRT7 CDKN2A
32	anal paget's disease	10.4	PIP KRT7
33	breast hemangioma	10.4	TP53 KRT7
34	childhood leptomeningeal melanoma	10.4	NRAS HRAS
35	female urethral cancer	10.4	KRT7 CDKN2A
36	nasal cavity adenocarcinoma	10.4	KRT7 HRAS
37	adenoid basal cell carcinoma	10.3	KRT7 KIT
38	bizarre leiomyoma	10.3	TP53 KIT CDKN2A
39	endometrial squamous cell carcinoma	10.3	TP53 KRT7 CDKN2A
40	melphalan allergy	10.3	NRAS CD274
41	vulvar eccrine porocarcinoma	10.3	PIP CDKN2A
42	eosinophilic variant of chromophobe renal cell carcinoma	10.3	KRT7 KIT
43	middle ear squamous cell carcinoma	10.3	GP5 CDKN2A
44	penis basal cell carcinoma	10.3	GP5 CDKN2A
45	bladder urachal carcinoma	10.3	KRT7 HRAS
46	lung adenoid cystic carcinoma	10.3	KRT7 KIT
47	neurofibrosarcoma	10.3	TP53 KIT CDKN2A
48	bladder clear cell adenocarcinoma	10.3	TP53 KRT7 CDKN2A
49	male urethral cancer	10.3	TP53 KRT7 CDKN2A
50	urachus cancer	10.3	KRT7 HRAS

Graphical network of the top 20 diseases related to Vulvar Disease:

Sources

Symptoms & Phenotypes for Vulvar Disease

UMLS symptoms related to Vulvar Disease:

pelvic pain; pruritus vulvae

GenomeRNAi Phenotypes related to Vulvar Disease according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.66	EGFR HRAS PIK3CA
2	Decreased viability	GR00055-A-2	9.66	EGFR HRAS PIK3CA
3	Decreased viability	GR00221-A-1	9.66	CDKN2A EGFR HRAS KIT NRAS PIK3CA
4	Decreased viability	GR00221-A-2	9.66	HRAS PIK3CA
5	Decreased viability	GR00221-A-3	9.66	CDKN2A HRAS NRAS
6	Decreased viability	GR00221-A-4	9.66	CDKN2A EGFR PIK3CA
7	Decreased viability	GR00301-A	9.66	KIT
8	Decreased viability	GR00402-S-2	9.66	PIK3CA

MGI Mouse Phenotypes related to Vulvar Disease:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.13	CDKN2A EGFR ERBB2 HRAS KIT NRAS
2	normal	MP:0002873	10.11	EGFR ERBB2 GP5 HRAS KIT MIR499A
3	endocrine/exocrine gland	MP:0005379	10.07	CDKN2A EGFR ERBB2 HRAS KIT NRAS
4	muscle	MP:0005369	10.06	CDKN2A EGFR ERBB2 HRAS KIT MIR499A
5	no phenotypic analysis	MP:0003012	10.03	CD274 CDKN2A EGFR HRAS KIT NRAS
6	cellular	MP:0005384	10.03	CD274 CDKN2A EGFR ERBB2 KIT KRT7
7	digestive/alimentary	MP:0005381	10.02	CDKN2A EGFR ERBB2 HRAS KIT NRAS
8	pigmentation	MP:0001186	9.97	CDKN2A EGFR KIT NRAS PTEN TP53
9	respiratory system	MP:0005388	9.76	CDKN2A EGFR ERBB2 HRAS KIT MIR223
10	skeleton	MP:0005390	9.65	CD274 CDKN2A EGFR ERBB2 HRAS KIT
11	integument	MP:0010771	9.32	CD274 CDKN2A EGFR ERBB2 HRAS KIT

Sources

Drugs & Therapeutics for Vulvar Disease

Drugs for Vulvar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Neurotransmitter Agents

Phase 4

abobotulinumtoxinA

Phase 4

Botulinum Toxins, Type A

Phase 4

Cholinergic Agents

Phase 4

Nifedipine

Approved

Phase 3

21829-25-4

4485

Hormones

Phase 3

Vasodilator Agents

Phase 3

Calcium, Dietary

Phase 3

calcium channel blockers

Phase 3

Tocolytic Agents

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Capsaicin

Approved

Phase 1, Phase 2

404-86-4

1548943

Fludarabine

Approved

Phase 1, Phase 2

75607-67-9, 21679-14-1

30751 657237

Aldesleukin

Approved

Phase 1, Phase 2

110942-02-4

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Dermatologic Agents

Phase 1, Phase 2

Antiviral Agents

Phase 1, Phase 2

Anti-Infective Agents

Phase 1, Phase 2

Vaccines

Phase 1, Phase 2

Alkylating Agents

Phase 1, Phase 2

Antirheumatic Agents

Phase 1, Phase 2

Anti-Retroviral Agents

Phase 1, Phase 2

Antineoplastic Agents, Alkylating

Phase 1, Phase 2

Anti-HIV Agents

Phase 1, Phase 2

Immunosuppressive Agents

Phase 1, Phase 2

Immunologic Factors

Phase 1, Phase 2

Ropivacaine

Approved

Phase 1

84057-95-4

71273 175805

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 1

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 1

50-02-2

3003 5743

Methylene blue

Approved, Investigational

Phase 1

61-73-4

6099

Artesunate

Approved, Investigational

Phase 1

88495-63-0

6917864 5464098

Antiprotozoal Agents

Phase 1

Anthelmintics

Phase 1

Antiparasitic Agents

Phase 1

Antimalarials

Phase 1

Desipramine

Approved, Investigational

50-47-5

2995

Lidocaine

Approved, Vet_approved

137-58-6

3676

Bupivacaine

Approved, Investigational

2180-92-9, 38396-39-3

2474

Amitriptyline

Approved

50-48-6

2160

Baclofen

Approved

1134-47-0

2284

Estradiol

Approved, Investigational, Vet_approved

50-28-2

5757

Polyestradiol phosphate

Approved

28014-46-2

Testosterone

Approved, Investigational

58-22-0

5408 6013

Adrenergic Agents

Anti-Arrhythmia Agents

Sodium Channel Blockers

Psychotropic Drugs

Antidepressive Agents, Tricyclic

Antidepressive Agents

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Botox on Vulvar Vestibulitis	Unknown status	NCT00119886	Phase 4	Botulinum toxin
2	Topical Application of Nifedipine Cream for the Treatment of Vulvar Vestibulitis Syndrome	Completed	NCT00496184	Phase 3	Nifedipine cream topical application
3	Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis	Completed	NCT00004316	Phase 1, Phase 2	capsaicin
4	A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers	Recruiting	NCT02858310	Phase 1, Phase 2	Aldesleukin;Fludarabine;Cyclophosphamide
5	Evaluation of the Efficacy of Mixed Methylene Blue Compound Injection for the Treatment of Nonneoplastic Epithelial Disorders of Vulva.	Completed	NCT03200808	Phase 1	mixed methylene blue compound injection
6	A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3)	Active, not recruiting	NCT03792516	Phase 1	artesunate ointment 40%
7	Vulvar Vestibulitis Trial: Desipramine-Lidocaine	Completed	NCT00276068		topical lidocaine + oral desipramine, and/or placebo
8	Effects of Flourish HEC Vaginal Care System on Reduction of Pain in Women With Localized Provoked Vulvodynia	Enrolling by invitation	NCT05478746
9	Open Ended Chart Review of Adult Women Presenting to the Vulvar Mucosal Specialty Clinic at Northwestern University Department of Dermatology	Terminated	NCT02881229
10	Treatment Prior to Injection and Biopsy of the Vulva	Terminated	NCT03444727

Search NIH Clinical Center for Vulvar Disease

Cochrane evidence based reviews: vulvar diseases

Sources

Genetic Tests for Vulvar Disease

Sources

Anatomical Context for Vulvar Disease

Organs/tissues related to Vulvar Disease:

FMA: Vulva

MalaCards : Skin, Lymph Node, Breast

Sources

Publications for Vulvar Disease

Articles related to Vulvar Disease:

(show top 50) (show all 224)

#	Title	Authors	PMID	Year
1	Vulvar dermatoses: a cross-sectional 5-year study. Experience in a specialized vulvar unit. ⁴¹	Garcia-Souto F...Bernabeu-Wittel J	36089549	2022
2	Acute genital ulcers in a young girl: a clinical challenge: Lipschütz ulcer. ⁴¹	Schafer F...Miranda R	35840440	2022
3	The efficacy and safety of secondary focused ultrasound therapy for recurrence of non-neoplastic epithelial disorders of the vulva. ⁴¹	Li R...Jiang J	36202394	2022
4	Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience. ⁶²	Adorni M...Landoni F	34289750	2022
5	Vulvar Neoplasms (Part II). ⁶²	Sanchez I...Kraus CN	35218865	2022
6	Inflammatory Vulvar Dermatoses (Part I). ⁶²	Sanchez I...Kraus CN	35413374	2022
7	Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study. ⁶²	Schnack TH...Hogdall C	35483986	2022
8	Influence of Photodynamic Therapy on Lichen Sclerosus with Neoplastic Background. ⁶²	Bizon M...Sawicki W	35207373	2022
9	The Human Vulvar Microbiome: A Systematic Review. ⁶²	Pagan L...van Poelgeest MIE	34946169	2021
10	Wound complications following vulvar excision for nonmalignant lesions. ⁶²	Boyles GP...Cosgrove CM	36277453	2021
11	The perioperative effect of anesthetic drugs on the immune response in total intravenous anesthesia in patients undergoing minimally invasive gynecological surgery. ⁶²	Novac MB...Manolea MM	35673815	2021
12	Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes. ⁶²	MacDuffie E...Grover S	34493586	2021
13	Dermatographism with vulvar symptoms. ⁶²	Rivera S...Mirowski GW	34621958	2021
14	Superficial lymphatic drainage of the vulva and its relation to the regional nodes: An experimental study. ⁶²	Pavlista D...Eliska O	34590298	2021
15	Fractionated Carbon Dioxide Laser for the Treatment of Vulvar Lichen Sclerosus: A Randomized Controlled Trial. ⁶²	Mitchell L...Krapf JM	33957648	2021
16	Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: a prospective study. ⁶²	De Rosa N...Bifulco G	33404703	2021
17	Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy. ⁶²	Preti M...Benedetto C	33707570	2021
18	[Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting]. ⁶²	Horn LC...Kommission zur Erstellung der S2k-Leitlinie Vaginalkarzinom	33346872	2021
19	Diagnostic Criteria for Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. ⁶²	Heller DS...ISSVD Difficult Pathologic Diagnoses Committee	33105449	2021
20	Association Between Vulvar Squamous Intraepithelial Lesions and Psychiatric Illness. ⁶²	Bell SG...Welch KC	33181537	2021
21	Common Benign Chronic Vulvar Disorders. ⁶²	Ringel NE...Iglesia C	33118795	2020
22	Clinicopathologic Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. ⁶²	Day T...Scurry J	32976294	2020
23	The Vulvodynia Experience Questionnaire: Qualitative Development of a New Patient-Reported Outcome Measure for Vulvodynia. ⁶²	Goldstein AT...Christoph A	32900670	2020
24	Vaginal energy-based devices: characterization of adverse events based on the last decade of MAUDE safety reports. ⁶²	Wallace SL...Enemchukwu EA	33003133	2020
25	A Qualitative Exploration of Women's Experiences of Living With Chronic Vulvar Dermatoses. ⁶²	Sadownik LA...Smith KB	32741746	2020
26	A randomized clinical study of the treatment of white lesions of the vulva with a fractional ultrapulsed CO2 laser. ⁶²	Zhang L...Mao Z	32762229	2020
27	Vulvar diseases: Conditions in adults and children. ⁶²	Mauskar MM...Edwards L	31712170	2020
28	Vulvar diseases: Approach to the patient. ⁶²	Mauskar MM...Edwards L	31712174	2020
29	Vulvar quality of life index (VQLI) - A simple tool to measure quality of life in patients with vulvar disease. ⁶²	Saunderson RB...Fischer G	31984477	2020
30	Chronic Pelvic Pain: ACOG Practice Bulletin Summary, Number 218. ⁶²		32080045	2020
31	Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218. ⁶²		32080051	2020
32	Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease. ⁶²	Cizek SM...Hoefgen HR	31325588	2019
33	Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder. ⁶²	Mitchell L...Goldstein AT	31351850	2019
34	Basal cell carcinoma of the vulva: a case report and systematic review of the literature. ⁶²	Renati S...Burgin S	30506682	2019
35	No. 385-Indications for Pelvic Examination. ⁶²	Evans D...Altman AD	31331610	2019
36	What's New in Cosmetic Dermatology. ⁶²	Benedetto AV	30466684	2019
37	Vulvovaginal Disease Education in Canadian and American Gynecology Residency Programs: A Survey of Program Directors. ⁶²	Edwards C...Selk A	29570138	2018
38	"The Future of Vulvar Disease: New and Ongoing Challenges": Presidential Lecture - XXIV World Congress 2017, Mendoza, Argentina. ⁶²	Marchitelli C	29474239	2018
39	Diagnosis and Treatment of Vulvar Dermatoses. ⁶²	Stockdale CK...Boardman L	29324620	2018
40	Generalized unprovoked vulvodynia; A retrospective study on the efficacy of treatment with amitriptyline, gabapentin or pregabalin. ⁶²	van Beekhuizen HJ...van der Meijden WI	29202395	2018
41	Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. ⁶²	Chen Y...Eder SE	28934912	2017
42	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. ⁶²	Huh WK...Luxembourg A	28886907	2017
43	Evaluation and Management of Vulvar Disease. ⁶²	Venkatesan A	28778648	2017
44	High-Yield Vulvar Histopathology for the Clinician. ⁶²	Reutter JC	28778634	2017
45	Fissures, Herpes Simplex Virus, and Drug Reactions: Important Erosive Vulvar Disorders. ⁶²	Bohl TG	28778641	2017
46	A General Approach to the Evaluation and the Management of Vulvar Disorders. ⁶²	Cobos GA...Pomeranz MK	28778633	2017
47	Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy. ⁶²	Preti M...Micheletti L	28541626	2017
48	HPV status and favourable outcome in vulvar squamous cancer. ⁶²	Wakeham K...Graham SV	27864932	2017
49	Lichenoid vulvar disease: A review. ⁶²	Fruchter R...Pomeranz MK	28492056	2017
50	Extra Mammary Paget's Disease of Vulva-a Case Report. ⁶²	Tomar TS...Ramadas PT	27872543	2016

Sources

Genes for Vulvar Disease

Genes related to Vulvar Disease (0 elite genes):

(show all 25)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR223	MicroRNA 223	RNA Gene	8.15	DISEASES inferred ¹⁴ ¹⁴
2	MIR19B1	MicroRNA 19b-1	RNA Gene	7.89	DISEASES inferred ¹⁴ ¹⁴
3	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	7	DISEASES inferred ¹⁴
4	TP53	Tumor Protein P53	Protein Coding	6.8	DISEASES inferred ¹⁴
5	MIR4712	MicroRNA 4712	RNA Gene	6.15	DISEASES inferred ¹⁴
6	MIR499A	MicroRNA 499a	RNA Gene	6.11	DISEASES inferred ¹⁴ ¹⁴
7	MIR3147	MicroRNA 3147	RNA Gene	5.94	DISEASES inferred ¹⁴
8	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	5.9	DISEASES inferred ¹⁴
9	PRICKLE2-AS1	PRICKLE2 Antisense RNA 1	RNA Gene	5.87	DISEASES inferred ¹⁴
10	KRT7	Keratin 7	Protein Coding	5.87	DISEASES inferred ¹⁴
11	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	5.78	DISEASES inferred ¹⁴
12	CD274	CD274 Molecule	Protein Coding	5.74	DISEASES inferred ¹⁴
13	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	5.66	DISEASES inferred ¹⁴
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.6	DISEASES inferred ¹⁴
15	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	5.53	DISEASES inferred ¹⁴
16	PIP	Prolactin Induced Protein	Protein Coding	5.51	DISEASES inferred ¹⁴
17	GP5	Glycoprotein V Platelet	Protein Coding	5.47	DISEASES inferred ¹⁴
18	MIR590	MicroRNA 590	RNA Gene	5.43	DISEASES inferred ¹⁴
19	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	5.35	DISEASES inferred ¹⁴
20	PTEN	Phosphatase And Tensin Homolog	Protein Coding	5.23	DISEASES inferred ¹⁴
21	CCND1	Cyclin D1	Protein Coding	5.18	DISEASES inferred ¹⁴
22	SMARCB1	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1	Protein Coding	5.16	DISEASES inferred ¹⁴
23	MIR425	MicroRNA 425	RNA Gene	5.16	DISEASES inferred ¹⁴
24	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	5.13	DISEASES inferred ¹⁴
25	MIR100	MicroRNA 100	RNA Gene	5.13	DISEASES inferred ¹⁴

Sources

Variations for Vulvar Disease

Sources

Expression for Vulvar Disease

Search GEO for disease gene expression data for Vulvar Disease.

Sources

Pathways for Vulvar Disease

Pathways related to Vulvar Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 81)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.86	TP53 PTEN PIP NRAS KIT HRAS
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.83	CDKN2A EGFR ERBB2 GP5 HRAS KIT
3	Signal Transduction ⁶⁶	13.81	CD274 EGFR ERBB2 HRAS KIT NRAS
4	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.5	TP53 PTEN PIK3CA NRAS HRAS ERBB2
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.44	EGFR ERBB2 HRAS KIT NRAS PIP
6	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.41	EGFR ERBB2 HRAS KIT NRAS PIK3CA
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.33	PTEN PIP NRAS KIT HRAS ERBB2
8	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.1	TP53 PTEN PIK3CA KIT ERBB2 EGFR
9	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.1	TP53 PTEN NRAS KIT HRAS EGFR
10	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.97	TP53 PTEN PIK3CA NRAS KIT HRAS
11	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.95	TP53 PTEN PIK3CA HRAS EGFR CDKN2A
12	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.9	PTEN PIK3CA NRAS HRAS ERBB2 EGFR
13	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.86	PIK3CA NRAS KIT HRAS EGFR
14	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.83	CD274 EGFR ERBB2 HRAS KIT NRAS
15	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.71	PTEN PIK3CA KIT ERBB2 EGFR
16	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.67	TP53 PIK3CA NRAS KIT HRAS EGFR
17	Malignant pleural mesothelioma ⁷⁴	12.62	CD274 CDKN2A EGFR HRAS KIT PIK3CA
18	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.61	TP53 PIK3CA NRAS HRAS ERBB2 EGFR
19	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.49	TP53 PTEN PIK3CA HRAS ERBB2
20	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.46	TP53 PIK3CA NRAS HRAS ERBB2 EGFR
21	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.44	EGFR HRAS NRAS PIK3CA
22	MAPK signaling pathway ⁷⁴	12.43	TP53 NRAS HRAS EGFR
23	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.43	TP53 PIK3CA NRAS HRAS ERBB2 EGFR
24	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.43	TP53 PTEN PIK3CA NRAS KIT HRAS
25	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.4	PIK3CA NRAS KIT HRAS ERBB2 EGFR
26	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.36	EGFR ERBB2 HRAS PIK3CA
27	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.35	PTEN PIK3CA NRAS HRAS
28	Focal adhesion ⁷⁴	12.32	PTEN PIK3CA HRAS ERBB2 EGFR
29	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.29	TP53 PTEN PIK3CA HRAS
30	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.29	EGFR ERBB2 HRAS KIT NRAS PIK3CA
31	Ras signaling ⁷⁴	12.27	PIK3CA NRAS KIT HRAS EGFR
32	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.26	EGFR ERBB2 HRAS NRAS PIK3CA
33	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.24	PTEN NRAS HRAS EGFR
34	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.19	NRAS HRAS ERBB2 EGFR
35	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.16	TP53 PTEN PIK3CA HRAS CDKN2A
36	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.16	TP53 PTEN PIK3CA NRAS HRAS ERBB2
37	mTOR Signaling ⁶⁵	12.14	TP53 PTEN ERBB2 EGFR
38	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.14	PTEN PIK3CA HRAS ERBB2 EGFR
39	Signaling by EGFR in Cancer ⁶⁶ Show member pathways Constitutive Signaling by EGFRvIII ⁶⁶ Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants ⁶⁶ EGFR interacts with phospholipase C-gamma ⁶⁶ EGFR-dependent Endothelin signaling events ⁶¹ GRB2 events in EGFR signaling ⁶⁶ SHC1 events in EGFR signaling ⁶⁶ Signaling by EGFRvIII in Cancer ⁶⁶ Signaling by Ligand-Responsive EGFR Variants in Cancer ⁶⁶	12.13	PIK3CA NRAS HRAS EGFR
40	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.08	PIK3CA NRAS HRAS ERBB2 EGFR
41	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.06	TP53 PIK3CA ERBB2 EGFR
42	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	12.04	PTEN PIK3CA KIT HRAS
43	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.04	PIK3CA NRAS HRAS ERBB2 EGFR
44	Senescence and autophagy in cancer ⁷⁴	11.98	CDKN2A HRAS PTEN TP53
45	Gastrin signaling pathway ⁷⁴	11.96	CDKN2A EGFR HRAS KIT PIK3CA
46	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.94	PIK3CA NRAS KIT HRAS
47	Signaling by EGFR ⁶⁶ Show member pathways EGFR downregulation ⁶⁶ GAB1 signalosome ⁶⁶	11.93	PIK3CA NRAS HRAS EGFR
48	Small cell lung cancer ⁷⁴	11.92	TP53 PTEN PIK3CA
49	Signaling by Erythropoietin ⁶⁶ Show member pathways EPO signaling pathway ⁶¹ Erythropoietin activates Phosphoinositide-3-kinase (PI3K) ⁶⁶ Erythropoietin activates Phospholipase C gamma (PLCG) ⁶⁶ Erythropoietin activates RAS ⁶⁶ Erythropoietin activates STAT5 ⁶⁶	11.91	PIK3CA NRAS HRAS
50	FGFR1 mutant receptor activation ⁶⁶ Show member pathways Signaling by cytosolic FGFR1 fusion mutants ⁶⁶ Signaling by FGFR1 in disease ⁶⁶ Signaling by plasma membrane FGFR1 fusions ⁶⁶	11.89	PIK3CA NRAS HRAS

Sources

GO Terms for Vulvar Disease

Biological processes related to Vulvar Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell migration	GO:0030335	10.02	MIR590 KIT HRAS EGFR CD274
2	Ras protein signal transduction	GO:0007265	9.92	TP53 NRAS HRAS CDKN2A
3	phosphatidylinositol 3-kinase signaling	GO:0014065	9.91	PTEN PIK3CA ERBB2
4	positive regulation of cell population proliferation	GO:0008284	9.9	PTEN MIR590 MIR19B1 KIT HRAS ERBB2
5	positive regulation of MAP kinase activity	GO:0043406	9.86	EGFR ERBB2 HRAS KIT
6	positive regulation of gene expression	GO:0010628	9.61	TP53 PIP MIR223 KIT HRAS ERBB2
7	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.58	ERBB2 CDKN2A
8	positive regulation of miRNA maturation	GO:1903800	9.46	TP53 EGFR
9	regulation of cell population proliferation	GO:0042127	9.17	TP53 KIT HRAS ERBB2 EGFR